The absence of fully validated prospective biomarkers and generally valid risk scores stratifying treatment outcome has led to a return to a clinical definition of high-risk CLL: as being described by dual resistance towards BTK and BCL2 inhibition (46). The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.